Dylan Gagler

Dylan Gagler

Auto-generated profile, based on publicly available information

Dylan Gagler

University of Arkansas for Medical Sciences 7 New-York, NY

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2025 in Blood
Verified
Journal Article
Closed access
DGDylan C. Gagler
Dylan C. Gagler
HGHussein Ghamlouch
Hussein Ghamlouch
DZDi Zhang
Di Zhang
PBPatrick Blaney
Patrick Blaney
ATAvital Tenenbaum
Avital Tenenbaum
GMGareth J. Morgan
Gareth J. Morgan
We carried out a single-cell multiomic analysis on a series of MYD88-mutated Waldenström macroglobulinemia (WM) patients and identified 2 distinct subtypes of disease, memory B-cell (MBC)–like and plasma cell (PC)–like, based on their expression of key lineage defining genes. Biologically, the subtypes are characterized by their variable capacity to differentiate fully toward a PC and exhibit unique transcriptomic, chromatin accessibility, and genomic profiles. The MBC-like subtype is unable to differentiate beyond the MBC stage, upregulates key MBC genes, and is characterized by upregulated B-cell receptor and phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) signaling. In contrast, the PC-like subtype can partially differentiate toward a PC, upregulates key PC genes, has enhanced NF-κB signaling, and has an upregulated unfolded protein response. Pseudotime trajectory analysis of combined single-cell RNA sequencing and single-cell assay for transposase-accessible chromatin with sequencing supports the variable differentiation capacity of each subtype and implicate key transcription factors SPI1, SPIB, BCL11A, and XBP1 in these features. The existence and generalizability of the 2 disease subtypes were validated further using hierarchical clustering of bulk RNA-sequencing data from a secondary set of patients. The biological significance of the subtypes was further established using whole-genome sequencing, in which it was shown that CXCR4, NIK, and ARID1A mutations occur predominantly in the MBC-like subtype, and 6q deletions in the PC-like subtype. We conclude that the variable differentiation blockade seen in WM manifests itself clinically as 2 disease subtypes with distinct epigenetic, mutational, transcriptional, and clinical features, with potential implications for WM treatment strategies.

14 July 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
EBEileen M. Boyle
Eileen M. Boyle
PBPatrick Blaney
Patrick Blaney
JSJames H. Stoeckle
James H. Stoeckle
YWYubao Wang
Yubao Wang
HGHussein Ghamlouch
Hussein Ghamlouch
GMGareth John Morgan
Gareth John Morgan
Purpose: Chromosome 1 (chr1) copy-number abnormalities (CNA) and structural variants (SV) are frequent in newly diagnosed multiple myeloma (NDMM) and are associated with a heterogeneous impact on outcomes, the drivers of which are largely unknown. Experimental Design: A multiomic approach comprising CRISPR, gene mapping of CNAs and SVs, methylation, expression, and mutational analysis was used to document the extent of chr1 molecular variants and their impact on pathway utilization. Results: We identified two distinct groups of gain(1q): focal gains associated with limited gene-expression changes and a neutral prognosis, and whole-arm gains, which are associated with substantial gene-expression changes, complex genetics, and an adverse prognosis. CRISPR identified a number of dependencies on chr1 but only limited variants associated with acquired CNAs. We identified seven regions of deletion, nine of gain, three of chromothripsis (CT), and two of templated insertion (TI), which contain a number of potential drivers. An additional mechanism involving hypomethylation of genes at 1q may contribute to the aberrant gene expression of a number of genes. Expression changes associated with whole-arm gains were substantial and gene set enrichment analysis identified metabolic processes, apoptotic resistance, signaling via the MAPK pathway, and upregulation of transcription factors as being key drivers of the adverse prognosis associated with these variants. Conclusions: Multiple layers of genetic complexity impact the phenotype associated with CNAs on chr1 to generate its associated clinical phenotype. Whole-arm gains of 1q are the critically important prognostic group that deregulate multiple pathways, which may offer therapeutic vulnerabilities.

12 June 2026 in Blood Cancer Discovery
Verified
Journal Article
Closed access
KMKylee H. Maclachlan
Kylee H. Maclachlan
MPMarios Papadimitriou
Marios Papadimitriou
PBPatrick Blaney
Patrick Blaney
LBLinda B. Baughn
Linda B. Baughn
TSTala Shekarkhand
Tala Shekarkhand
GMGareth John Morgan
Gareth John Morgan
Studies have reported conflicting findings regarding the contribution of germline variants or somatic genomic drivers to racial disparities in multiple myeloma (MM). To comprehensively investigate somatic drivers in relation to inherited genetics in MM, we combined newly sequenced whole-genome sequencing data with publicly available datasets (total n = 1,286). Overall, we did not identify germline or somatic genomic differences that explain the different risk of developing MM between patients with genetic similarity to African (AFR) or European (EUR) reference populations. A difference in the detectability and timing of APOBEC-associated and germinal center mutational activity was observed. Integrating epidemiological data and mutational signature-based temporal estimates, we challenge the assumption that individuals in the AFR group develop MM at a younger age. Finally, we demonstrate that, with equal access to efficacious therapies, patients in the AFR and EUR groups have equivalent clinical outcomes.

25 November 2025
Verified
Other
Open access
EBEileen M. Boyle
Eileen M. Boyle
PBPatrick Blaney
Patrick Blaney
JSJames H. Stoeckle
James H. Stoeckle
YWYubao Wang
Yubao Wang
HGHussein Ghamlouch
Hussein Ghamlouch
GMGareth John Morgan
Gareth John Morgan
Differential expression between patients with no 1q gain and those with a gain(1q:CKS1B). A. All genes that are differentially expressed

25 November 2025
Verified
Other
Open access
EBEileen M. Boyle
Eileen M. Boyle
PBPatrick Blaney
Patrick Blaney
JSJames H. Stoeckle
James H. Stoeckle
YWYubao Wang
Yubao Wang
HGHussein Ghamlouch
Hussein Ghamlouch
GMGareth John Morgan
Gareth John Morgan
Chromatin state of different gain region. The regions of gain tend to fall within active chromatin regions with G3, G4, G5, G6, and G8 lying exclusively within A-compartments (100%) across B-cell differentiation states and MM cell lines (U266, RPMI8226, and KMS11). The G1 region also followed this pattern with the exception of KMS11 (where A-compartment represented only 78% of the region). The G2 region showed variability between the normal and malignant phenotype, with moderate switching from to B-compartments of 24%, 21%, and 37% in U266, RPMI8226, and KMS11 respectively. The compartment profile of the G7 region is interesting as each sample contained considerable B-compartment percentage (range 16-82%) but within the conserved A-compartment across all samples lies the well characterised oncogene ABL2. The G9 region showed the greatest variability across all samples and was shifted more towards inactive chromatin (range 45-97%). NBC=Naïve B-cell, MBC=Memory B-cell, GCBC=Germinal Center B-cell, PC=plasma cell.

25 November 2025
Verified
Other
Open access
EBEileen M. Boyle
Eileen M. Boyle
PBPatrick Blaney
Patrick Blaney
JSJames H. Stoeckle
James H. Stoeckle
YWYubao Wang
Yubao Wang
HGHussein Ghamlouch
Hussein Ghamlouch
GMGareth John Morgan
Gareth John Morgan
Recurrent chromosome 1 mutations. Ninety-five genes on chromosome 1 that are mutated in more than 1% of cases in the Myeloma Genome Project dataset.